Polysaccharide meningococcal vaccines--current status.
Two separate periods of intensive research, with a 25-year hiatus after the advent of the sulfonamides, have resulted in two good, but imperfect, antimeningococcal vaccines--against serogroups A and C. Neither is recommended for routine use, but both have been effective in halting epidemics. Lack of an effective group B immunogen remains the major obstacle to the control of meningococcal disease.
D000328:Adult; D000367:Age Factors; D000917:Antibody Formation; D001426:Bacterial Proteins / Q000276:immunology; D001428:Bacterial Vaccines / Q000302:isolation & purification*; D002675:Child, Preschool; D003429:Cross Reactions; D004196:Disease Outbreaks / Q000517:prevention & control; D006801:Humans; D007223:Infant; D008565:Membrane Proteins / Q000276:immunology; D008585:Meningitis, Meningococcal / Q000517:prevention & control*; D009345:Neisseria meningitidis / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology* / Q000302:isolation & purification
D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D008565:Membrane Proteins; D011135:Polysaccharides, Bacterial